🔍

Supriya Lifescience Limited (SUPRIYA)

₹886.00 +1.54% last close, 16 Oct

📊 NSE: SUPRIYA 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📢 Latest filing: 13 Oct 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Supriya Lifescience's revenue was ₹190 Cr (+30.8% year on year, -31.5% on the previous quarter), and net profit ₹24.0 Cr (-30.9% year on year); the operating margin was 25.0%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹190	+30.8%	-31.5%
Operating profit	₹47.5	-8.2%	-51.6%
Net profit	₹24.0	-30.9%	-67.5%
EPS (₹)	2.99	-30.8%	-67.6%
Operating margin	25.0%	—	—

Full quarterly financials → Results calendar →

SUPRIYA delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 46.55% of the SUPRIYA shares traded on NSE were taken to delivery, against the stock's own 20-session average of 41.21%. That is close to its usual level.

46.55%Delivery, 16 Oct

41.21%Own 20-session average

0.5×Volume vs its average

₹886.00NSE close · +1.54%

Delivery in the last 5 sessions: 37.0% · 43.4% · 48.8% · 45.6% · 46.5%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Supriya Lifescience Assigned 'CRISIL ESG 65' Rating in 'Strong' Category

🟡 NEUTRAL ⭐ 3/10

OTHER 📅 13 Oct 2026, 02:08 PM

Supriya Lifescience Limited announced that CRISIL ESG Ratings & Analytics Limited has voluntarily assigned it an ESG rating of 'CRISIL ESG 65'. This rating places the company in CRISIL's 'Strong' category. The disclosure is made pursuant to Regulation 30 under SEBI LODR rules and SEBI's Master Circular on ESG ratings dated January 30, 2026. The rating has no direct impact on immediate earnings or balance sheet figures.

Voluntarily assigned ESG rating of 'CRISIL ESG 65'
Assigned rating category classified as 'Strong'
Disclosed in compliance with SEBI Master Circular dated January 30, 2026

💡 Monitor upcoming quarterly earnings and operational updates; ESG ratings do not alter operational cash flows or business fundamentals in the short term.

Supriya Lifescience Submits Reg 74(5) Dematerialisation Certificate for Q2 FY27

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 12 Oct 2026, 04:13 PM

Supriya Lifescience Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited, confirms compliance for the quarter ended September 30, 2026. It verifies that share certificates received for dematerialisation during the quarter were duly processed, listed on stock exchanges, and mutilated as per required timelines. This is a regular administrative disclosure with zero financial impact.

Compliance certificate submitted under Regulation 74(5) of SEBI Regulations, 2018
Covers the quarter ended September 30, 2026
Issued by RTA MUFG Intime India Private Limited dated October 03, 2026
Confirmation that dematerialised shares were processed and listed within prescribed timelines

💡 Track upcoming announcements regarding the company's Q2 FY27 financial results and operational updates.

Supriya Lifescience Files Petition in Supreme Court Challenging High Court Order

🔵 WATCH ⭐ 4/10

LEGAL 📅 08 Oct 2026, 04:48 PM

Supriya Lifescience Limited has filed a petition before the Supreme Court of India on October 8, 2026. This filing follows an earlier order from the High Court dated September 23, 2026. The matter is currently sub judice, and the company has refrained from commenting on the merits or financial exposure of the proceedings. Investors should monitor subsequent court disclosures as the details of the underlying dispute remain unquantified in this brief update.

Petition filed before the Supreme Court of India on October 8, 2026
Matter follows an earlier High Court order disclosed on September 23, 2026
Underlying financial claim and nature of dispute not disclosed in the filing

💡 Track subsequent exchange intimations regarding Supreme Court admission hearings and potential legal or financial liability disclosures.

Supriya Lifescience Shareholders Approve Re. 1.00 Final Dividend and All AGM Resolutions

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Sep 2026, 09:55 PM

Supriya Lifescience has concluded its 18th Annual General Meeting held on September 24, 2026, with all ordinary resolutions approved by over 99.7% shareholder majorities. Among the approved items is a final dividend of Re. 1.00 (50%) per equity share of Rs 2 face value for FY 2025-26, supported by 99.9973% of votes. The re-appointments of whole-time directors Dr. Saloni Wagh and Ms. Shivani Wagh upon retirement by rotation were also ratified. Financial statements for FY 2025-26 and cost auditor remuneration ratification were similarly passed.

Final dividend of Re. 1.00 (50%) per Rs 2 equity share approved with 99.9973% assent
Adoption of FY 2025-26 audited financial statements passed with 99.9974% assent
Re-appointment of Director Dr. Saloni Wagh passed with 99.7621% assent (1,38,328 dissent votes)
Re-appointment of Director Ms. Shivani Wagh approved with 99.9958% assent
Cost auditor remuneration ratification for FY 2026-27 approved with 99.9963% assent

💡 Track the upcoming Q2 FY 2027 results and monitor export market execution in regulated geographies.

Bombay HC Allows Provisional Release of 200 kg Ketamine Consignment on ₹72 Lakh Deposit

🔵 WATCH ⭐ 5/10

LEGAL 📅 23 Sep 2026, 11:32 AM

Supriya Lifescience received an order from the Hon'ble High Court of Bombay permitting the provisional release of a seized consignment of 200 kg of Ketamine Hydrochloride. The release is subject to a deposit of ₹72 lakh with the Assistant Commissioner of Customs, Export, within one week of the order dated September 22, 2026. However, the court clarified that authorities may continue adjudication and criminal proceedings under applicable laws, including Section 52A of the NDPS Act. The ₹72 lakh deposit is minor relative to the company's net worth of ₹1,198 crore and quarterly net profit of ₹49.68 crore (Dec 2025), but legal risks remain pending.

Bombay HC allowed provisional release of 200 kg Ketamine Hydrochloride consignment under Shipping Bill No. 3780061.
Provisional release requires a deposit of ₹72 lakh with Customs within one week.
Court clarified that adjudication and criminal proceedings may continue as per law.
Authorities are permitted to follow procedures under Section 52A of the NDPS Act.

💡 Monitor upcoming filings for updates on the ongoing adjudication and any criminal proceedings under the NDPS Act.

Supriya Lifescience Schedules Virtual Institutional Investor Group Meeting for September 17, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Sep 2026, 04:46 PM

Supriya Lifescience Limited has notified the exchanges regarding a scheduled group meeting with analysts and institutional investors. The virtual meeting is set to take place on Thursday, September 17, 2026, from 11:00 AM to 12:00 NOON. The company confirmed that its investor presentation is already available on its website and the stock exchange platforms. This is an administrative disclosure under Regulation 30(6) of SEBI LODR Regulations.

Virtual group interaction scheduled for Thursday, September 17, 2026
Meeting duration set from 11:00 AM to 12:00 NOON
Updated investor presentation already uploaded on stock exchanges and corporate website
Intimation filed pursuant to Regulation 30(6) of SEBI LODR Regulations, 2015

💡 Investors should look out for any subsequent post-meet disclosures or updated investor presentations to identify updates regarding product launches in regulated markets.

Supriya Lifescience Dispatches FY26 Annual Report Weblink; 18th AGM Scheduled for Sept 24, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Sep 2026, 06:23 PM

Supriya Lifescience Limited has sent letters containing the web link to its FY2025-26 Annual Report to shareholders without registered email addresses as of the August 21, 2026 cut-off date. The company announced that its 18th Annual General Meeting (AGM) will be held virtually on Thursday, September 24, 2026, at 3:00 PM IST. This is a standard statutory compliance filing under Regulation 36(1) of the SEBI LODR Regulations.

18th Annual General Meeting scheduled for Thursday, September 24, 2026, at 3:00 PM IST via VC/OAVM
Communication sent to shareholders whose email addresses are unregistered as on August 21, 2026
Soft copy of Annual Report for FY2025-26 accessible on the company and stock exchange websites
Filing made pursuant to Regulation 36(1) of SEBI LODR Regulations

💡 Track the 18th AGM proceedings and voting resolutions on September 24, 2026, alongside upcoming Q2 FY27 financial results.

Supriya Lifescience: Judicial Proceedings of GM Sales & Marketing Remain Sub Judice

🟡 NEUTRAL ⭐ 3/10

LEGAL 📅 02 Sep 2026, 05:32 PM

Supriya Lifescience Limited has submitted an update confirming that the judicial proceedings involving its General Manager – Sales & Marketing continue to remain sub judice. The matter is currently awaiting hearing and adjudication before the Hon'ble Court of Law. As of September 2, 2026, no further orders or developments have taken place following previous disclosures on July 4, August 14, and August 18, 2026. The company stated it will notify exchanges upon any material development or court order.

Legal proceedings involving GM – Sales & Marketing remain sub judice awaiting adjudication.
Prior disclosures on the matter were made on July 4, 2026, August 14, 2026, and August 18, 2026.
No new orders or developments have been passed by the Court as of September 2, 2026.

💡 Track future stock exchange disclosures for any formal court rulings or operational impact arising from the case.

Supriya Lifescience Convenes 18th AGM on Sep 24; Re. 1/Share Final Dividend Record Date Sep 4

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 01 Sep 2026, 07:55 PM

Supriya Lifescience Limited has issued the notice for its 18th Annual General Meeting (AGM) scheduled for September 24, 2026, via video conferencing. The company is seeking shareholder approval for a final dividend of Re. 1.00 (50%) per equity share of face value ₹2 for FY 2025-26. The record date to determine dividend entitlement has been fixed as Friday, September 4, 2026, with payouts commencing on or after September 24, 2026. Other business includes the ratification of cost auditor remuneration of ₹2,50,000 and the re-appointment of directors Dr. Saloni Satish Wagh and Ms. Shivani Satish Wagh retiring by rotation.

18th AGM scheduled for Thursday, September 24, 2026, at 3:00 PM IST via VC/OAVM
Final dividend of Re. 1.00 (50%) per equity share of face value ₹2 proposed for FY 2025-26
Record date for dividend entitlement fixed as September 4, 2026
Cost auditor remuneration for FY 2026-27 proposed at ₹2,50,000 plus applicable taxes

💡 Track the ex-dividend date around September 4, 2026, to qualify for the final dividend, and monitor voting outcomes following the AGM on September 24, 2026.

Supriya Lifescience Sets Sep 4, 2026 Record Date for ₹1.00/Share Final Dividend

🟡 NEUTRAL ⭐ 5/10

DIVIDEND 📅 26 Aug 2026, 05:29 PM

Supriya Lifescience Limited has fixed Friday, September 4, 2026, as the record date for determining shareholder entitlement to a final dividend of ₹1.00 per equity share (face value ₹2.00 each) for FY 2025-26. The dividend was recommended by the Board on May 27, 2026, and is subject to shareholder approval at the upcoming Annual General Meeting (AGM) on September 24, 2026. If approved, the dividend will be disbursed within 30 days of the AGM.

Final dividend recommended at ₹1.00 per equity share of face value ₹2.00 each for FY 2025-26
Record date fixed as Friday, September 4, 2026
18th AGM scheduled for Thursday, September 24, 2026 at 3:00 p.m. IST via Video Conferencing
Dividend payment to be completed within 30 days of shareholder approval at the AGM

💡 Investors seeking dividend eligibility must hold shares in their demat accounts prior to the record date of September 4, 2026, and track AGM voting outcomes on September 24, 2026.

Supriya Lifescience Approves Re-Appointment of WTD Balasaheb Sawant with 99.69% Favour Votes

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 22 Aug 2026, 01:05 PM

Supriya Lifescience Limited has announced the completion of its postal ballot through remote e-voting. Shareholders approved the special resolution for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel for a 3-year term from May 26, 2026, to May 25, 2029. The resolution passed overwhelmingly with 99.69% of votes (5,81,00,796 votes) cast in favour out of 5,82,81,483 total votes polled. Total voter turnout stood at 72.41% of total outstanding equity shares across 79,554 registered shareholders as of the record date.

Re-appointment of Mr. Balasaheb Sawant approved for a 3-year term from May 26, 2026, to May 25, 2029
99.69% of votes cast in favour (5,81,00,796 votes) vs 0.31% against (1,80,687 votes)
Overall voter participation stood at 72.41% of total 8,04,82,800 equity shares
Eligible shareholder base stood at 79,554 on the cut-off date of July 17, 2026

💡 This is a routine governance approval ensuring leadership continuity; watch upcoming quarterly earnings and execution on finished formulations capacity.

Q1 FY27 Revenue Up 31% YoY to Rs 190 Cr; EBITDA Margin Dips to 25% on Cost Headwinds

🟡 NEUTRAL ⭐ 5/10

EARNINGS 📅 18 Aug 2026, 04:37 PM

Supriya Lifescience reported Q1 FY27 revenue of Rs 190 crore, up 31% YoY, despite a Rs 35 crore sales deferment caused by localized water scarcity. EBITDA declined 8.1% YoY to Rs 47 crore with margins contracting to 25%, weighed down by Rs 10.5 crore in transient cost headwinds including a Maharashtra solar power policy change (Rs 8 crore impact) and elevated solvent costs. Net profit came in at Rs 24 crore against Rs 35 crore in Q1 FY26. Management reiterated its full-year guidance of delivering normalized EBITDA margins of 33%-35% and reaching Rs 1,000 crore revenue by FY27, backed by a planned Rs 200 crore Phase-1 capex at Patalganga.

Q1 FY27 revenue rose 31% YoY to Rs 190 crore, impacted by Rs 35 crore in deferred sales due to water shortages
EBITDA decreased 8.1% YoY to Rs 47 crore with EBITDA margin at 25% due to Rs 10.5 crore in temporary cost pressures
Net profit dropped to Rs 24 crore compared to Rs 35 crore in Q1 FY26
Management reaffirmed midterm revenue target of Rs 1,000 crore by FY27 and EBITDA margin band of 33%-35%
Earmarked ~Rs 200 crore for Phase-1 Patalganga capex (~16.7% of Rs 1,198 crore Net Worth), funded partly via Rs 150 crore in cash reserves

💡 Track the recovery of the Rs 35 crore deferred sales and verify whether EBITDA margins recover toward the guided 33%-35% band in Q2 FY27 results.

Supriya Lifescience Releases Audio Recording of Q1 FY27 Earnings Call

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 14 Aug 2026, 05:21 PM

Supriya Lifescience has informed the exchanges that the audio recording of its earnings call held on August 14, 2026, is now available on its website. The call discussed the company's operational and financial performance for the quarter ended June 30, 2026. This is a standard regulatory compliance following the disclosure of quarterly results. Investors can access the recording to understand management's perspective on the quarter's performance.

Earnings call conducted on August 14, 2026, to discuss Q1 FY27 performance.
Recording pertains to the financial results for the quarter ended June 30, 2026.
Follows prior intimations sent to the exchanges on August 10 and August 13, 2026.
Management previously guided for stabilized margins of 33%-35% in the midterm.

💡 Investors should review the recording for management commentary on export growth (currently 81% of revenue) and the progress of the finished formulation business.

31% Revenue Growth in Q1 FY27 but PAT Drops 31% as Margins Contract

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 13 Aug 2026, 11:27 PM

Supriya Lifescience reported a strong 30.8% YoY revenue growth to ₹189.75 Cr for Q1 FY27, driven by expansion in Asia and the Vitamin segment. However, profitability faced significant pressure as EBITDA margins contracted sharply from 35.6% to 25.0%, leading to an 8.2% YoY decline in EBITDA. Consequently, PAT fell 30.9% YoY to ₹24.04 Cr. While the top-line growth is robust, the substantial margin compression reflects potential pricing headwinds or higher operational costs during its transition into finished dosages.

Revenue increased 30.8% YoY to ₹189.75 Cr from ₹145.07 Cr in Q1 FY26.
EBITDA margin compressed by 1,060 basis points to 25.0% compared to 35.6% in the previous year.
Profit After Tax (PAT) declined 30.9% YoY to ₹24.04 Cr from ₹34.79 Cr.
Asia became the largest market contributing 39% of revenue, up from 32% YoY.
Capacity utilization stood at 70% for the quarter, down from 74% in FY26.

💡 Investors should monitor the stabilization of margins as the company scales its new finished dosage facility at Ambernath and tracks the ramp-up of the ADHD and Cardiovascular product pipelines.

Supriya Lifescience Q1 PAT Drops 31% YoY to ₹24.04 Cr Despite 31% Revenue Growth

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 13 Aug 2026, 07:38 PM

Supriya Lifescience reported a weak Q1 FY27 with Net Profit (PAT) declining 30.9% YoY to ₹24.04 cr, despite a 30.8% increase in Revenue from Operations to ₹189.75 cr. The profitability was severely impacted by a 149.9% surge in raw material costs, which rose to ₹109.40 cr from ₹43.78 cr in the previous year. Sequentially, the performance was even more subdued, with revenue and PAT falling 31.4% and 67.6% respectively compared to Q4 FY26. A specific note mentions that export goods detained by Customs were recognized as sales, which warrants attention regarding revenue certainty.

Revenue from operations grew 30.8% YoY to ₹189.75 cr, but fell 31.4% sequentially from ₹276.53 cr.
Net Profit (PAT) contracted 30.9% YoY to ₹24.04 cr, down from ₹34.79 cr in Q1 FY26.
Cost of materials consumed spiked to ₹109.40 cr, representing 57.6% of revenue compared to 30.2% in the year-ago quarter.
Total expenses increased by 51.1% YoY to ₹151.60 cr, significantly outpacing revenue growth.
Basic EPS for the quarter stood at ₹2.99, down from ₹4.32 in Q1 FY26 and ₹9.22 in Q4 FY26.

💡 Investors should monitor the stabilization of raw material costs and management's ability to pass on these costs to maintain their midterm margin guidance of 33-35%. The resolution of the Customs detention issue mentioned in the notes is also a key monitorable for revenue realization.

View All SUPRIYA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company reported revenue from operations of INR 200 crores for Q2 FY '26, representing a 20% year-on-year growth compared to INR 166 crores in Q2 FY '25. Sequentially, revenue grew by 38%. Historical revenue has grown from INR 3,912 million in FY21 to INR 6,965 million in FY25.

Geographic Revenue Split

Exports are the cornerstone of the business, accounting for 81% of total revenue in Q2 FY '26. Foreign exchange earnings for the year ended March 31, 2025, were INR 5,286 million compared to INR 4,498.14 million in the previous year.

Profitability Margins

The company reported a PAT of INR 50.43 crores for Q2 FY '26 with a PAT margin of 25.2%. For the half-year ended September 30, 2025, PAT stood at INR 85.22 crores. Management guides for a stabilized margin of 33%-35% in the midterm as products transition from semi-regulated to regulated markets.

EBITDA Margin

EBITDA for Q2 FY '26 was INR 73 crores, a 12% year-on-year increase and 41% sequential increase. The EBITDA margin for the quarter was 36%, which is in line with management guidance.

Capital Expenditure

Capital expenditure has increased significantly, with FY25 capex spend at INR 1,623 million. As of September 30, 2025, Capital Work in Progress (CWIP) stood at INR 1,725 million, up from INR 1,480 million in March 2025. Property, plant, and equipment were valued at INR 4,519 million.

Credit Rating & Borrowing

ICRA upgraded the short-term rating to [ICRA]A1 from [ICRA]A2+. The company maintains a healthy leverage profile with a Debt/Equity ratio of 0.01 as of FY25. Total equity stood at INR 10,818 million as of September 2025.

⚙️ Operational Drivers

Manufacturing Efficiency

Management emphasizes 'execution excellence' and 'operational efficiency' as strategic levers to sustain growth and navigate operational challenges effectively.

📈 Strategic Growth

New Products/Services

The company is launching new products in regulated markets and is bringing a finished formulation business on stream to add to margins.

Market Expansion

The strategy involves scaling up in semi-regulated markets and maturing products into regulated markets where entry barriers are higher and pricing is better.

Strategic growth analysis not yet available for this company.